Zhimeng Biopharma

Zhimeng Biopharma is a biopharmaceutical company that develops novel small molecule drugs to treat neurological diseases, including epilepsy, pain, and strokes. The company also focuses on chronic Hepatitis B cure development and has an investigational drug, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS). Their website, core-biopharma.com, provides information about their products and services.

The company's website, core-biopharma.com, is described by multiple reviewers as informative, user-friendly, and easy to navigate. Reviewers consistently praise the helpfulness of the website in making purchase decisions and understanding their offerings. The site is noted for providing all necessary information to potential customers.

Zhimeng Biopharma has received a Trustburn rating of 4 out of 5 stars from 9 reviews. The review split includes several 5-star ratings, with some 4-star and 3-star ratings as well. These reviews are dated from December 2022 to July 2023, showing recent customer feedback.

The company is actively developing CB03-154, a next-generation potassium channel opener for ALS, which successfully completed patient enrollment in its pivotal Phase 2/3 clinical trial in October 2026. Additionally, their drug CB03 received Orphan Drug Designation from the US FDA as a potassium ion channel opener for amyotrophic lateral sclerosis.

According to news sources, Zhimeng Biopharma has appointed global partners for its development of a Chronic Hepatitis B cure. The company is also recognized in the Hepatitis B Virus Pipeline Assessment 2022 report as a major player in this field.

The company's core competencies include the development of IDO inhibitors, specifically an IDO1 inhibitor initially developed by Shanghai Zhimeng Biopharma, Inc. This drug is currently pending its highest R&D status according to drug target databases.

Reviewers frequently mention that Zhimeng Biopharma provides top-notch quality products and services. Many customers express satisfaction with the high quality of the products and the professionalism of the company in delivering these items.

The company's history includes significant milestones such as receiving FDA Orphan Drug Designation and completing pivotal clinical trial enrollments. These events demonstrate a track record of advancing drug development through regulatory approvals and clinical progress.